30 closest matches · ranked by relevance
Multiple Myeloma
Primary: Percentage of Patients With MRD(-) Remissions at the Completion of Consolidation Therapy — 81.4 percentage of patients achieving MRD (-)
Multiple Myeloma · Smoldering Multiple Myeloma · Monoclonal Gammopathy of Undetermined Significance
Primary: Count of Participants With Positive and Negative 18F-FDG PET CT and F18-NaF PET CT Imaging Results in Individuals With MGUS, SMM, and MM. — 0; 1; 5; 10 Participants
Smoldering Multiple Myeloma
Primary: 2 Year Progression Free Percent — 62.5 percentage of participants
Multiple Myeloma
Primary: Number of Participants Who Experienced a Dose-Limiting Toxicity (DLT) — 0; 0; 0; 0 Participants
Multiple Myeloma
Primary: Absence of Dose Limiting Toxicity — 3; 1; 3; 9 Participants
Multiple Myeloma
Primary: Combined Response Rate During the Induction Phase in Newly Diagnosed Multiple Myeloma (NDMM) Participants — 27; 24 percentage of participants — p=0.4859
Multiple Myeloma
Primary: Response Rates by Blade Criteria — 2; 5; 3; 2 Participants
Multiple Myeloma
Primary: Percentage of Participants With Minimal Residual Disease (MRD)Negative Complete Response (CR) Per International Myeloma Working Group (IMWG) Criteria — 70.4 percentage…
Refractory Multiple Myeloma · Smoldering Multiple Myeloma · Stage I Multiple Myeloma
Primary: Maximum Tolerated Dose (MTD) — 1600 cGy
Multiple Myeloma
Primary: Number of Participants With Stringent Complete Response (sCR) — 17 Participants
Amyloidosis · Plasma Cell Myeloma
Primary: Maximum Tolerated (MTD) Dose of Cyclophosphamide With Ixazomib and Dexamethasone (Phase I) — 4; 40 mg weekly
Smoldering Multiple Myeloma
Primary: Proportion Of High Risk SMM Patients Who Are Progression Free 2 Years After Receiving IRD Combination Therapy — 50 Participants
Smoldering Multiple Myeloma
Primary: Proportion of Subjects With a Downgraded Risk of Progression of Smoldering Multiple Myeloma if the Risk Category Decreases. — 0 proportion of participants
Multiple Myeloma
Primary: Percentage of Participants That Are Relapse-free 5 Years After Initial Therapy — 28 percentage of participants
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Overall Response Rate (Complete and Partial) — 77.50 percentage of participants
Multiple Myeloma
Primary: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Ixazomib (Phase 1) — 3; 4; 3; 4 mg
Multiple Myeloma
Primary: Rate of Patients Achieving a Response Based on M-protein or Free Light Chains — 0; 1 participants
Multiple Myeloma
Primary: Change in Serum Osteocalcin From Baseline to End of Study in Patients With Relapsed/Refractory Multiple Myeloma. — 20.00 ng/ML
Multiple Myeloma
Primary: Bone Formation Markers Measurement — 21.87; 23.2; 1.33; 28.75 U/L — p=0.002
Multiple Myeloma
Primary: Maximum Tolerated Dose (MTD) — NA mg/kg
Multiple Myeloma
Primary: Immune Response — 7 Particpants
Smoldering Multiple Myeloma
Primary: Rate of Patients Achieving an Objective Response — 0; 0 participants
Relapsed, Refractory or Plateau Phase Multiple Myeloma
Primary: Response Rate [Complete Response (CR) and Partial Response (PR)] — 0; 0; 0; 1 participants
Extramedullary Plasmacytoma · Isolated Plasmacytoma of Bone · Light Chain Deposition Disease
Primary: Median Progression Free Survival (mPFS) — 76.4 months
Multiple Myeloma
Primary: Phase I: Number of Patients With Dose Limiting Toxicity — 0; 0; 0; 0 Participants
Multiple Myeloma
Primary: Progression-free Survival (PFS) After Initiation of Pomalidomide Therapy — 13 percentage of participants
Relapsed or Plateau-Phase Multiple Myeloma
Primary: Complete Response or Partial Response Based on M-Protein Assessments Only — 0; 0 Participants
Smoldering Myeloma · Smoldering Multiple Myeloma
Primary: Percent of Patients Who Are Progression Free at 2 Years — 45.0; 36.4 percentage of participants
Multiple Myeloma, Relapsed · Multiple Myeloma, Refractory to Standard Treatment
Primary: Maximum Tolerated Dose (MTD) of Gy — NA Participants
Amyloidosis
Primary: Maximum Tolerated Dose — 2 participants with DLT